by Gus Iversen
, Editor in Chief | April 23, 2015
The demand for proton therapy continues to vastly outweigh the availability of treatment, but IBA's ever-increasing global footprint is helping to resolve that problem.
Their latest installation is under contract with University Medical Center Groningen (UMCG) and will bring proton therapy to the Netherlands.
The renowned academic facility emphasizes healthy aging medical research and employs almost 12,000 workers, making it the largest employer in the north of the country. Some 3,400 University of Groningen students are aspiring medical professionals and the school hosts over 450 medical residencies.
Headquartered in Belgium and employing about 1100 people worldwide, IBA has installed systems across the world, from Europe and the U.S. to emerging markets. Olivier Legrain, IBA's CEO, said more than half of the worldwide proton therapy market is equipped by IBA. Due to that footprint, roughly 40,000 patients have been treated on their systems - more than all major competitive installations combined, said Legrain.
SRI is a leading Developer, Manufacturer & Supplier of Innovative Portable Imaging Equipment. We offer Lightweight, Agile, Easy to Maneuver Portable X-Ray Systems ideal for maneuvering in tight spaces. Call us at 631-244-8200
"The professional support and responsiveness that IBA has demonstrated throughout our demanding tender procedure gives us confidence in a successful and long-lasting collaboration with them," said Bert-Jan Souman, Managing Director of the ProtonTherapyCenterGroningen at the UMCG. "We are now eager to see the Proton Therapy center opening its doors in 2017 and to provide this technology for the benefit of thousands of cancer patients in Holland"
"Following a rigorous public tender process, we are delighted that IBA has been selected as the best proton therapy provider to build the first ever proton therapy center in The Netherlands," said Legrain. "Thanks to our unique experience, we are committed to supporting UMCG to provide high-quality cancer treatment to more patients across the region."